Adjunctive therapy with 25-hydroxyvitamin D

A hydroxyvitamin, patient technology, applied in the field of adjunctive therapy utilizing 25‑hydroxyvitamin D, which can solve the problems of limited efficacy of antiresorptive drugs, definition of supplementation regimen, etc.

Inactive Publication Date: 2017-04-26
OPKO IRELAND GLOBAL HLDG LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The prevalence and persistence of SHPT even with vitamin D and calcium supplementation in patients receiving antiresorptive therapy suggests that an appropriate supplementation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] One embodiment of the modified release formulation for oral administration

[0096] Pure yellow beeswax and fractionated coconut oil were combined in a 1:1 ratio and heated to 75°C with continuous mixing until a homogeneous mixture was obtained. Continue homogenizing the wax mixture while cooling to about 45°C. The active compound 25-hydroxyvitamin D in a 1:1 ratio 2 and 25-hydroxyvitamin D 3 Dissolve in absolute ethanol and add the ethanol solution with continuous homogenization to obtain a molten wax mixture. The amount of ethanol added is in the range of 1 to 2 v / v%. Continue mixing until the mixture is homogeneous. The homogeneous mixture is filled into soft gelatin capsules. The capsules were rinsed immediately to remove any processing lubricants and briefly soaked in aqueous acetaldehyde to crosslink the gelatin shell. The concentration of the acetaldehyde solution and soaking time are selected to achieve the desired degree of crosslinking, which can be dete...

Embodiment 2

[0098] One embodiment of the formulation for intravenous administration

[0099] Heat TWEEN Polysorbate 20 to approximately 50 to 60°F and add 25-Hydroxyvitamin D dissolved in a minimum volume of absolute ethanol with continuous stirring 3 . The resulting 25-hydroxyvitamin D 3 , absolute ethanol, and TWEEN polysorbate 20 were transferred to an appropriate volume of water for injection, which had been flushed sufficiently with nitrogen to remove all dissolved oxygen. Sodium chloride, sodium ascorbate, sodium phosphate (dibasic and monobasic) and disodium ethylenediaminetetraacetate are added, followed by vigorous stirring under a nitrogen atmosphere, to yield an aliquoted homogeneous mixture containing per 2 mL unit volume: 20 mcg 25-Hydroxyvitamin D 3 ; less than 0.01% absolute alcohol; 0.40% (w / v) TWEEN polysorbate 20; 0.15% (w / v) sodium chloride; 1.00% (w / v) sodium ascorbate; 0.75% (w / v) ) disodium hydrogen phosphate anhydrous; 0.18% (w / v) sodium dihydrogen phosphate mon...

Embodiment 3

[0101] Pharmacokinetic Testing in Dogs

[0102] Twenty male beagles were randomized into two comparison groups and received no vitamin D supplementation for the next 30 days. At the end of this time, each dog in Group #1 received 25-hydroxyvitamin D containing 25mcg in a controlled release formulation similar to that disclosed in Example 1 2 single soft capsule. Each dog in the other group (Group #2) received 25-hydroxyvitamin D containing 25mcg dissolved in medium chain triglyceride oil 2 A single immediate-release softgel. All dogs had not received food for at least 8 hours prior to dosing. Blood was drawn from each dog at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 15, 24, 36 and 72 hours post-dose. The collected blood was analyzed for the concentration of 25-hydroxyvitamin D contained, and the data were analyzed by treatment group. Mean blood 25-hydroxyvitamin D concentrations in dogs in Group #1 showed a slower and maximal increase compared to dogs in Group #2 (C max )smaller. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Description

[0001] Cross References to Related Applications [0002] This article claims the benefit of U.S. Provisional Patent Application No. 62 / 034,604, filed August 7, 2014, the disclosure of which is incorporated herein by reference under 35 U.S.C. § 119(e). Background technique [0003] 25-Hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 (collectively referred to as "25-hydroxyvitamin D"), vitamin D metabolites are provitamin D hormones that contribute to maintaining adequate levels of vitamin D hormones, calcium and phosphorus in the bloodstream. Primarily via one or more enzymes located in the liver, the prohormone 25-hydroxyvitamin D 2 by vitamin D 2 (ergocalciferol (ergocalciferol)), and 25-hydroxyvitamin D 3 (calcifediol) from vitamin D 3 (cholecalciferol (cholecalciferol)) produced. These two prohormones are also produced outside the liver by vitamin D in certain cells that contain the same or similar enzymes as those found in the liver, such as intestinal epithelial cells ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/592A61K31/593A61K45/06A61P5/20A61P5/22A61P19/08A61P19/10A61P35/00A61P35/04
CPCA61K31/592A61K31/593A61K45/06A61K2300/00A61K9/0019A61K47/26A61K9/4875A61K31/675A61K39/395A61K2039/505C07K2317/21C07K2317/76A61P13/12A61P19/08A61P19/10A61P3/02A61P3/14A61P35/00A61P35/04A61P5/06A61P5/20A61P5/22A61P7/08A61K31/137A61K47/38A61K47/44A61K31/135A61K47/14A61K47/06A61K9/0053A61L2300/00A61K31/663A61K9/4825A61K38/23
Inventor 马丁·P·佩特科维奇乔尔·Z·梅尔尼克杰伊·A·怀特萨米尔·P·塔巴什查理斯·W·比绍夫苏珊·H·皮尔斯斯蒂芬·A·斯特拉格内尔
Owner OPKO IRELAND GLOBAL HLDG LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap